NurExone Biologic (FRA:J90) Total Long-Term Assets: €1.25 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J90 NurExone Biologic Inc FRA:J90
38 GF Score
Price €0.26
! 2 Warning Signs
View Full Analysis

What is NurExone Biologic Total Long-Term Assets?

NurExone Biologic FRA:J90 +5.24% 38 Total Long-Term Assets is €1.25 Mil as of Mar. 2026. GuruFocus rates FRA:J90 with a GF Score™ of 38/100. The stock has 2 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. NurExone Biologic's Total Long-Term Assets for the quarter that ended in Mar. 2026 was €1.25 Mil.

NurExone Biologic Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for NurExone Biologic's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NurExone Biologic Total Long-Term Assets Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
0.00 0.10 0.17 0.77 1.27

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.72 0.79 1.28 1.27 1.25
FRA:J90
38GF Score
NurExone Biologic Inc FRA:J90
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NurExone Biologic Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of €1.25 Mil mean?
NurExone Biologic (FRA:J90) has a Total Long-Term Assets of €1.25 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on NurExone Biologic and its competitors.
Is NurExone Biologic's Total Long-Term Assets too high?
NurExone Biologic's current Total Long-Term Assets is €1.25 Mil. Overall, NurExone Biologic has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does NurExone Biologic's Total Long-Term Assets compare to VRTX and REGN?
NurExone Biologic's Total Long-Term Assets of €1.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on NurExone Biologic and its competitors. NurExone Biologic's current Total Long-Term Assets is €1.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NurExone Biologic stock overvalued right now?
NurExone Biologic (FRA:J90) has a current Total Long-Term Assets of €1.25 Mil. The current Total Long-Term Assets is €1.25 Mil. NurExone Biologic's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For NurExone Biologic (FRA:J90), the current Total Long-Term Assets is €1.25 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NurExone Biologic Business Description

Other Exchanges NRXBF:USANRX:Canada
Address 1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Its primary product is ExoTherapy, which is an exosome therapy production platform. It is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). It also aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.
38GF Score

Get the complete analysis for FRA:J90

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.26
Price